Purdue Loses Case To Stop Generic OxyContin

By Andrew Karpan · April 11, 2023, 10:27 PM EDT

The bankrupt Purdue Pharma lost its legal effort to use patent laws to block an Indian drugmaker from launching a generic version of OxyContin when a federal judge in Delaware decided...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

Purdue Pharma L.P. et al v. Accord Healthcare Inc.

Case Number

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

October 08, 2020

Recent Articles By Andrew

February 12, 2025
Labcorp Can't Score New Trial After $384M Patent Loss
February 06, 2025
Drug Cos. Urge Full Fed. Circ. To Hear Teva Orange Book Row
January 08, 2025
Patent Board Knocks Out Most Of Apple Patent
January 08, 2025
Telligen's TM Suit Against IT Co. Can Move Forward
January 06, 2025
Labcorp Loses Appeal Of Gene-Testing Patent In $372M Case
December 04, 2024
Withers IP Partners Hop To Sullivan & Worcester
December 02, 2024
Judge Isn't Seeing 'Good Faith' Compliance In Probiotic Feud
November 22, 2024
Wellness Software Co. Not Immune From IP Suit, Judge Says
November 19, 2024
Judge Rejects Infosys' Bid To Seal NDAs In Trade Secrets Row
November 18, 2024
Melinta Obtains Ban On Generic Antibiotic Injections In IP Row